RE:RE:RE:RE:ONCY’s Phase 1b/2 mPC results compared over 2019 to 2023On October 16, 2023 the GOBLET Phase 1/2 metastatic pancreatic cancer abstract was released at ESMO and reported on updated results in patients who were treated with pelareorep + atezolizumab + chemotherapy (gemcitabine + nab-paclitaxel). These results showed a significant improvement over the historical control of gemcitabine + nab-paclitaxel.
Preliminary GOBLET results were updated PDAC data showing a median PFS of 7.2 months, interim median overall survival of 10.6 months, expansion of both pre-existing and new T-cell clones and a 6-month survival rate of 82% in a patient population comprised of patients where 92% presented with metastatic disease, 69% in the liver - the worst of the worst - which historically has only 10% of these metastatic pancreatic patients living longer than one (1) year.